Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
European Journal of Nuclear Medicine and Molecular Imaging
External validation of an established prognostic score in an independent cohort, demonstrating reproducibility of risk stratification and survival prediction with robust performance metrics, but not introducing new clinical intervention or changing treatment selection.
European Journal of Nuclear Medicine and Molecular Imaging
First dosimetry characterization of 161Tb-PSMA-617 in a small, uncontrolled registry cohort without clinical outcome data, providing absorbed dose estimates but lacking efficacy, safety or comparative evidence.
A narrative review synthesizing clinical trial evidence, regulatory approvals, and translational findings to propose a strategic framework for advancing Lu-177 radiopharmaceutical therapy, rather than reporting a primary empirical result.
A retrospective single-centre analysis of metastasis-directed SBRT in oligo-recurrent prostate cancer showing feasible local control and delayed systemic therapy, but lacking a comparator and prospective design.
Descriptive comparative immunohistochemistry study raising mechanistic questions about CREB phosphorylation regulation in primate versus human prostate tissue, without clinical outcome data or functional validation.
Large real-world retrospective cohort with prospectively collected data, clear PSA endpoints, and adjusted analysis demonstrating consistent superiority of ARSI-based regimens over ADT monotherapy in mCSPC, though limited by surrogate endpoints and lack of hard clinical outcomes.
Mechanistic study in cell culture identifying a putative regulatory axis; lacks clinical validation, patient outcomes, or prospective testing needed to support therapeutic claims.
Retrospective cohort study with clear associations between PSA dynamics, metastatic status and time to progression, but limited by single-country setting, lack of multivariate adjustment, and no comparison group receiving alternative therapy.